曲妥珠单抗联合全脑放疗治疗 HER2+乳腺癌脑转移患者的疗效和安全性

Treatment of brain metastases in patients with HER2+ breast cancer.

机构信息

Instituto Português de Oncologia de Francisco Gentil, Lisboa, 1099-023, Portugal.

出版信息

Adv Ther. 2009 Jul;26 Suppl 1:S18-26. doi: 10.1007/s12325-009-0047-0. Epub 2009 Jul 24.

Abstract

Brain metastases are a frequent complication of cancer. However, effective treatments are available. This article aims to review clinical aspects of patients with brain metastases discussing the various treatment options for such patients. It will address the importance and significance of brain metastases in patients with breast cancer and, finally, review the problem of brain metastasis associated with human epidermal growth factor receptor 2-positive (HER2+) breast cancer. With ever-improving survival rates of patients with cancer, there is a greater likelihood that many will develop brain metastases. Treatments such as whole brain or stereotactic radiotherapy and surgery have been shown to be effective against brain metastases. In HER2+ breast cancer, trastuzumab has been shown to be very effective, although it cannot cross the blood-brain barrier. If patients with breast cancer who are being treated with trastuzumab and are responding systemically, develop brain metastases, then patient prognosis does need to be taken into account; however, maintaining treatment with trastuzumab while using available therapies to treat intracranial lesions should be considered as an option.

摘要

脑转移是癌症的常见并发症。然而,有效的治疗方法是可用的。本文旨在回顾脑转移患者的临床方面,讨论此类患者的各种治疗选择。它将探讨脑转移在乳腺癌患者中的重要性和意义,最后,回顾与人类表皮生长因子受体 2 阳性(HER2+)乳腺癌相关的脑转移问题。随着癌症患者生存率的不断提高,许多人更有可能发展为脑转移。全脑或立体定向放疗和手术等治疗方法已被证明对脑转移有效。在 HER2+乳腺癌中,曲妥珠单抗已被证明非常有效,尽管它不能穿过血脑屏障。如果正在接受曲妥珠单抗治疗且全身反应良好的乳腺癌患者出现脑转移,则需要考虑患者的预后;然而,在考虑使用现有疗法治疗颅内病变的同时,继续使用曲妥珠单抗治疗应被视为一种选择。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索